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Introduction: As yet, there is no patient-assessed, condition-specific instrument for the assessment of health-related
quality of life in intermittent claudication. We evaluated the intermittent claudication questionnaire (ICQ) for properties
required of a measure of health outcome.
Methods and results: Interviews with patients with intermittent claudication and vascular specialist opinion produced a
pool of statements used to itemize a self-completed ICQ. This was piloted in 20 patients for practicality and then
administered to 124 stable claudicants. Reliability was assessed through a retest in 63 (51%) patients at 14 days and
analysis of Cronbach’s  for internal consistency. Spearman’s correlation coefficient was used to assess construct validity
in comparisons between the ICQ and ankle brachial pressure index, treadmill-walking distances, the walking impairment
questionnaire, the EuroQol, and the Short Form–36. Responsiveness of the ICQ to changes in health was assessed in 60
patients treated conservatively and 40 patients undergoing angioplasty. The standardized response mean was used to
identify the most responsive instrument in the study. A 16-item ICQ with a test-retest intraclass correlation of 0.95 and
Cronbach’s  of .94 was produced. One hundred twenty-one (98%) patients completed the ICQ (mean time, 3.7
minutes). The ICQ correlated better with the EuroQol (r  0.58) and 7 out of 8 subscales of the Short Form–36 (r 
0.33-0.68) compared with the walking impairment questionnaire. The ICQ demonstrated the largest standardized
response mean in relation to health transition compared with the other instruments.
Conclusions: The patient-assessed ICQ is a practical, reliable, valid, and responsive measure of patient health–related
quality of life in intermittent claudication. (J Vasc Surg 2002;36:764-71.)
INTRODUCTION
Background. Intermittent claudication (IC) affects
between 0.3%and 7.7% of the population, with an age-
related increase in incidence and prevalence rates.1 Al-
though progression to severe limb-threatening ischemia
with rest pain and tissue loss is possible, more than 75% of
patients have stable conditions, with only a 1.5% to 2%
5-year risk of amputation.2,3 More significantly, functional
disability from mobility impairment may lead to disability
and a drop in quality of life (QOL) because of the inability
to cope with the personal, social, or occupational demands
of daily living.4 Treatment for most patients is conservative
with cardiovascular risk factor modulation5,6 and the intro-
duction of antiplatelet therapy.7 In addition, patients are
advised to exercise, and some centers advocate supervised
exercise therapy classes.8,9 Interventional treatment op-
tions, such as angioplasty or surgical revascularisation, carry
inherent risks, including limb loss,10 with the additional
benefit of angioplasty over exercise therapy remaining yet
unclear.11,12
Difficulties with existing outcome measures. Tradi-
tionally, the endpoints chosen in IC studies have been
treadmill walking ability13-16 for exercise therapy studies or
measures of patency like duplex scanning17 or ankle pres-
sures18 for interventional therapy studies. This difference in
endpoints has made the comparison of treatment options
difficult.19 Of late, increasing interest is seen in the assess-
ment of QOL impairment in IC. The recent TransAtlantic
Inter-Society Consensus (TASC) states that if QOL could
be accurately assessed, then it should be the ideal primary
endpoint.20 As yet, no patient-assessed condition-specific
instrument exists for the assessment of health-related QOL
in IC.21
Walking distance. Surgeons have focused mainly on
assessments of walking distance as an endpoint for IC.
Unfortunately, verbal estimates of walking distance in clinic
are not only subjective but also highly inaccurate.22 Thus, a
more objective method of measuring walking distance,
such as treadmill testing, has been used. Fixed load tread-
mill testing suffers from a lack of reproducibility, with up to
three tests necessary for reproducible evaluation.23 Pro-
gressive load treadmill testing has better reproducibility
and is preferred in clinical trials.20,24 With either treadmill
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protocol, the absolute claudication time (ACT) or point of
maximum pain threshold is more reproducible than the
initial claudication time or point of onset of pain.25-27
Reservations against treadmill testing include the possible
“learning” bias in studies that use it as a mode of training
and of outcome testing,28 the inability of some patients
with claudication with coexisting cardiac, respiratory, or
lumbar disease to reach ACT,29 and the view that treadmill
distances do not correlate with the patient’s perception of
disability.30
Questionnaire-based health outcome measures.
Patient-assessed health outcome measures can be generic
or condition specific. Generic instruments, such as the
Short Form-36 (SF-36),31,32 the Nottingham Health Pro-
file,33 and the EuroQol,34-37 have been previously used in
claudication studies. Because they are designed for applica-
tion with other conditions, they may fail to focus on IC and
thus miss small but important changes of QOL in patients
with claudication.
The Walking Impairment Questionnaire (WIQ) is a
function-specific measure of outcome14,38 that does not
adequately address the QOL concerns of the patients with
claudication. The WIQ is interviewer administered and
based around patient estimates of claudication symptom
severity, walking distance, walking speed, and stair climb-
ing ability. Thus, it relies on the accuracy of patient estima-
tion of walking and stair climbing ability but does not
consider the role limitations of patients with claudication.
A German Claudication Scale (CLAU-S)39,40 has been
developed, and although translations in French, Flemish,
and English exist, there is no published validation of the
English version. Designed to be condition specific, at least
four of nine subscales are derived from the Profile of Mood
States,41 an instrument for measuring the affective state of
a patient. The original version listed 80 items and required
18 minutes to score. A revised version has five subscales
with a total of 47 items and has been validated in France.42
To date, no IC-specific patient-assessed instrument for
QOL assessment in the English language literature exists.
We therefore describe the development, validation, and
testing for responsiveness of such an instrument, the Inter-
mittent Claudication Questionnaire (ICQ).
METHODOLOGY
Patient selection for the study. Consecutive patients
referred to the outpatient clinic with IC between January
and December 1999 were selected for the study on the
basis of an appropriate history (ie, pain in the calves, thighs,
or buttocks after a period of exercise that is relieved by rest),
a positive response to a diagnostic tool for IC, the Edin-
burgh Claudication Questionnaire,43 and resting ankle bra-
chial pressure index (ABPI) measurement of less than or
equal to 0.9.
Development of the instrument and reliability test-
ing. Semistructured interviews were conducted with new
patients with claudication to elicit how their condition
affected their life style. This produced a pool of statements
describing the impact of IC on patient QOL that formed
the content of items or questions for the new self-adminis-
tered instrument. Four vascular specialists (two vascular
surgeons and two vascular nurses) provided expert opinion
for content validity. The resultant instrument uses five
point adjectival scales (Appendix, online only).
Pilot testing for acceptability and practicality was per-
formed in a small sample of patients to assess questionnaire
completion times, content relevance, and readability. Am-
biguous or incomprehensible items were reworded or re-
moved. The ICQ then was assessed for measurement prop-
erties in the larger cohort of patients who satisfied our
inclusion criteria. Individual items with large amounts of
missing data, poor endorsement frequencies, and end ef-
fects (floor and ceiling) were removed. Principle compo-
nent analysis (PCA) was used to identify separate compo-
nents or dimensions of health within the instrument. A
component was considered important if it made a substan-
tial contribution to the explanation of the variation be-
tween patients and if it had content validity.44 Items with
poor component loadings (a measure of the contribution
to individual dimensions) on the dimensions identified
through PCA and items with low levels of item-total cor-
relation (between an item and the remainder of the scale)
also were removed.
Reliability was assessed with methods of internal con-
sistency and test-retest. Internal consistency reliability was
assessed with Cronbach’s ,45 which measures the average
level of correlation between items within a scale and should
exceed 0.7.46 Test-retest reliability was assessed with the
intraclass correlation (ICC)47 between instrument scores
over time for patients with stable symptoms between ad-
ministrations. With a health transition question (eg, “Com-
pared to 2 weeks ago, are your leg pains: much worse/
somewhat worse/about the same/somewhat better/much
better?”), a subsample of patients with stable symptoms at 2
weeks was identified. These patients completed a second
ICQ at 2 weeks for assessment of test-retest reliability. An
ICC of 0.7 was regarded as an acceptable level of reproduc-
ibility.48
Validity testing. The instrument was evaluated for
content and construct validity.48 Content validity, which
was assessed through expert opinion, tested the adequacy
of the items in the instrument in spanning the entire range
of concerns relevant to the specific condition. Construct
validity consisted of correlating scores of the new instru-
ment with other accepted outcome measures in IC (eg, the
ABPI at rest, treadmill walking distances, and other ques-
tionnaire-based instruments, such as the SF-36, the Euro-
Qol, and the WIQ).
A combined questionnaire comprising the new instru-
ment (ICQ), the WIQ,14,38 the EuroQol,34-37,49 and the
SF-3631,32,50,51 was administered to all study patients at 0
months and 3 months (Table I). The WIQ was adminis-
tered with an interview, and the three other instruments
were self completed.
Supervised treadmill testing with a well-recognized
protocol that uses a fixed velocity of 2 miles per hour (3.2
km per hour) but with a graded increment in the gradient
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by 3.5 degrees every 3 minutes was used.52 All patients who
underwent treadmill testing had a 15-minute rest followed
by ABPI measurement before a series of warm-up exercises
for 5 minutes. Treadmill testing then was begun with pulse,
blood pressure, and electrocardiogram monitoring. Initial
claudication distance and absolute claudication distance on
the treadmill were recorded.
Responsiveness testing. The ICQ was administered
to a group of patients with IC who either underwent
angioplasty or remained on conservative therapy (risk factor
modulation and advice on smoking cessation and exercise
therapy). Responsiveness to changes in QOL with treat-
ment over time was quantified with the standardized re-
sponse mean (SRM),53 which is the mean change in score
for a scale divided by the standard deviation of the change.
At 3 months, a self-reported symptom transition question
was administered with the ICQ as an external criterion of
change (eg, “Compared to 3 months ago, how would you
rate your leg pains? – much worse/about the same/much
better”). Mean change scores were calculated with sub-
tracting baseline pretreatment scores from follow-up scores
at 3 months. Data were analysed with the Statistical Pack-
age for the Social Sciences (SPSS) software (SPSS v 9.0,
SPSS, Inc, Chicago, Ill).
RESULTS
Development and reliability testing. Initial patient
interviews (n  24) produced a pool of statements listing
the concerns raised because of leg pains. Interviews were
stopped after 24 patients because no new themes emerged.
From this list of themes describing the impact of IC on
various aspects of patient QOL and expert vascular special-
ist input, an 18-item, self-administered instrument, the ICQ,
was devised. All patients in the pilot study (n 20) found the
ICQ acceptable and easy to complete (mean completion time,
3.7 minutes), and no additional areas were added.
A total of 124 patients with claudication met the inclu-
sion criteria (Table II) and were administered the ICQ.
One hundred twenty-one patients completed the ICQ
(completion rate, 97.6%). One patient omitted three ques-
tions, one patient omitted two questions, and two patients
omitted one question each. Little evidence was found of
floor and ceiling effects. The largest proportion of patients
scoring at the floor was 59.4% for question 14 (“How much
time do your leg pains cause you to worry about money?”),
and the largest proportion of patients scoring at the ceiling
was 37.1% for question 6 (“Do your leg pains limit you
walking more than a mile?”).
PCA produced a three-component solution with eig-
envalues of more than 1.0. The three components ex-
plained 49.5%, 8.8%, and 6.4% of the total variation. Six-
teen of 18 items had loadings of more than 0.65 on the first
component. Items 13 (“How much of the time have you
worried that you may eventually lose a leg because of your
leg pains?”) and 14 (“How much time have your leg pains
caused you to worry about money”) were removed, which
improved the internal consistency of the instrument. The
results of PCA after removal of these two items are shown in
Table III. This produced a three-component solution ex-
plaining 53.0%, 7.9%, and 6.8% of the total variation. All
items had loadings of more than 0.65 on the first compo-
Table I. Instruments completed by study patients in assessment of ICQ validity
Instrument Type Dimensions or subscales Items
Average completion
times Cronbach’s  Scoring
WIQ14,19,43 Function-specific
interviewer-
administered
4
Symptom severity
Walking distance
Walking speed
Stair climbing
22 Average, 6 minutes NA 0 to 100% (0% worst;
100% best)
EuroQol40-42,54 Generic
self-administered
Single-utility measure
comprising 5 items:
Mobility
Self care
Usual activities
Pain/discomfort
Anxiety/depression
5 Short NA 243 combinations of
possible responses
ranging from –0.59
to 1.0 (–0.59 worst;
1.0 best)
SF-3636,37,55,56 Generic
self-administered
8
Physical functioning
Social functioning
Role: physical
Role: emotional
Pain
Vitality
Mental health
General health perception
36 Between 5 and 10
minutes
0.55 - 0.93 0 to 100 (0 worst; 100
best)
ICQ (Appendix) Condition-specific
self-administered
Single index
Health-related QOL from
IC
16 Average, 3.7 minutes 0.94 0 to 100 (0 best; 100
worst)
NA, Not applicable.
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nent, and this, together with the relatively large level of
variation explained by the first component, is evidence that
the instrument is measuring a single underlying construct.
Item-total correlations ranged from 0.62 to 0.76. The
16-item final ICQ (Appendix, online only) produced a
Cronbach’s  of 0.94. ICQ items use five-point or six-point
adjectival scales. The instrument is scored with summing up
patient responses to individual items, which are all equally
weighted, and transforming to a 0 to 100 scale, where 0 is
the best possible and 100 the worst possible health state.
The mean ICQ score for the group (n  121) was 42.55
(standard deviation, 19.54) and normally distributed.
Fifty-eight patients who reported no change in health
transition at 2 weeks underwent test-retest analysis. ICC of
the scores at 0 and 2 weeks was 0.95 (P  .01). This
indicated that the ICQ was stable over time in those pa-
tients with claudication whose symptoms were unchanged
in the 2-week interval. These reliability estimates are ac-
ceptable for use in individuals and in groups of patients.48
Validity testing. The Spearman correlation coeffi-
cient values between the ICQ with verbal reports of esti-
mated walking distance, initial and absolute treadmill clau-
dication distances (initial claudication distance and
absolute claudication distance), resting ABPI and scores of
the EuroQol, four components of the WIQ, and eight
domains of the SF-36 are summarized in Table IV. A
significant correlation (P  .001) was seen between the
ICQ with treadmill ACT, the EuroQol, all four compo-
nents of the WIQ, and all eight domains of the SF-36. The
level of correlation between the ICQ and the EuroQol and
SF-36 was greater than that for the WIQ components. The
only exception was for the WIQ component of walking
speed, which had a slightly larger correlation with the
SF-36 scale of vitality.
Responsiveness testing. A prospective sample of 100
patients with IC completed the ICQ for responsiveness
analysis. Sixty patients were treated conservatively, and 40
patients underwent percutaneous transluminal angioplasty
(Table II). The 60 patients with conservative treatment for
claudication also completed the EuroQol, the WIQ, and
the SF-36 in conjunction with the ICQ at 0 and 3 months
to allow the comparison of responsiveness of these instru-
ments through evaluation of the SRM. The results for the
mean changes in these instrument scores with the self-
reported heath transition question in the conservatively
treated group (n 60) and the resulting SRM for the ICQ,
the WIQ, the EuroQol, and the SF-36 at 3 months fol-
low-up are shown in Table V. Table VI shows the results of
ICQ scores for patients who underwent conservative treat-
Table III. Principal component analysis and item-total
correlation of ICQ items
ICQ items
Component
loading
Item-total
correlation
Severity of leg pains 0.70 0.66
Pain limits crossing road 0.78 0.76
Pain limits with bus, train, or tube 0.76 0.71
Pain limits climbing several flights of
stairs
0.67 0.62
Pain limits climbing one flight of
stairs
0.73 0.68
Pain limits walking more than 1 mile 0.71 0.67
Pain limits walking 100 yards 0.80 0.76
Pain limits leaving house 0.69 0.64
Pain stopped walking 0.73 0.68
Time spent thinking about legs
pains
0.70 0.65
Felt downhearted and low because
of pain
0.76 0.72
Time spent worrying that pains will
worsen
0.70 0.65
Interference with normal work 0.76 0.72
Interference with hobbies 0.66 0.61
Interference with social life 0.74 0.69
Interference with errands (eg,
shopping)
0.74 0.70
Table II. Patient characteristics
Development group*
(n  124)
Angioplasty group
(n  40)
Conservative group
(n  60)
Mean age (range; years) 71 (42 - 91) 70 (51 - 86) 70 (42 - 86)
Male gender 75 (61%) 32 (80%) 39 (65%)
History of:
Hypertension 60 (48%) 24 (60%) 29 (48%)
Diabetes 26 (21%) 9 (23%) 14 (23%)
Smoking 110 (81%) 37 (93%) 55 (92%)
Current smokers 35 (28%) NA NA
Median verbally estimated walking distance
(range; m)
183 (9 - 1829) 100 (5 - 800) 183 (9 - 1829)
Median resting ABPI (range)
Baseline 0.68 (0.39 - 0.90) 0.69 (0.38 - 0.97) 0.66 (0.36 - 0.90)
3 months NA 0.93 (0.35 - 1.00) 0.66 (0.38 - 1.00)
Median treadmill ICD (range; m) 96 (13 - 91) NA NA
Median treadmill ACD (range; m) 205 (30 - 1068) NA NA
*Screening exclusions: critical limb ischemia (rest pain or tissue loss); back pain; hip or knee arthritis; limiting cardiorespiratory disease; previous stroke and
hemiparesis; neurologic muscle weakness; drug or alcohol dependency; and chronic pain conditions other than leg pains from IC (eg, diabetic neuropathy).
NA, Not applicable; ICD, initial claudication distance; ACD, absolute claudication distance.
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ment (n  60) or angioplasty (n  40) at 0 and 3 months.
Sixty-three percent of patients (25/40) for angioplasty had
hemodynamic success (ABPI improving at least 0.15)
after angioplasty, whereas only 3% of patients (2/60) who
underwent conservative treatment had a significant hemo-
dynamic result. The ICQ was more responsive than the
other instruments and produced SRM values that repre-
sented a large level of change.
DISCUSSION
QOL assessment is becoming an increasingly impor-
tant issue in vascular surgery. This is especially relevant in
IC for which there is still no universally agreed outcome
measure. The recent TASC statement stressed that QOL
instruments should be used in all claudication trials and
ultimately, measurement of QOL may become the primary
endpoint.20,24 Although a new King’s College vascular
QOL questionnaire, the VascuQol, already exists for lower
limb ischemia, its suitability and validity as a specific out-
come measure for claudication trials is debatable because
patients with claudication are not primarily concerned with
the problems of tissue loss, rest pain, and limb loss present
in patients with critical ischemia.54 Four of 25 questions in
the VascuQol probe problems of rest pain and tissue loss
that are not relevant to IC. Therefore, its ability to detect
small but important changes in QOL impairment in pa-
tients with claudication over time and after treatment is
questionable.55
Our results for the ICQ show that it has internal
consistency and test-retest reliability values that exceed
standards required for the use of the instrument in individ-
ual patients for clinical practice and in patient groups for
clinical trials.56 Generally, for the use of an instrument for
groups of patients, a reliability coefficient of at least 0.70 is
required, and for decisions about individual patients, a
higher reliability coefficient of 0.95 is necessary.48 By con-
trast, the TASC statement20,24 highlights that these data
are often lacking in existing instruments. The evaluation of
the WIQ has not reported results for reliability testing but
has focused on tests of construct validity, including corre-
lations between WIQ scores and walking distances.38 Al-
though walking impairment is a feature of IC, evaluation of
this function alone does not fully address concerns of
patients with claudication regarding QOL impairment. For
example, a maximum walking distance of 50 m may be a
disability to one patient but may be perfectly acceptable to
another. Treatment should aim to improve overall QOL in
patients, and walking speed, walking distance, or stair
climbing ability as assessed with the WIQ form only aspects
of that improvement. For this reason, only four of 16 items
listed in the ICQ evaluate walking distance and stair climb-
ing ability (Appendix, online only). They require simpler
responses than the WIQ, which demands a complex degree
of differentiation by each patient for walking speed, walking
distance, and stair climbing ability.
The ICQ was more highly correlated with the EuroQol
and the SF-36 than the WIQ (Table IV), which is evidence
that it better reflects the impact of IC on broader aspects of
health as assessed with the generic instruments. These
results suggest that QOL in IC is attributable to a limitation
in the patient’s daily routine physical activities, interference
Table IV. Correlation between ICQ, WIQ, and other existing outcome measures
Instrument ICQ Pain
WIQ components
Walking
distance
Walking
speed
Stair
climbing
Verbal estimate of walking distance –0.17 0.27 0.18 0.25 0.16
ICD –0.28 0.49* 0.28 0.22 0.32
ACD –0.38* 0.52* 0.31 0.31 0.38
Resting ABPI –0.14 0.08 0.14 0.15 0.07
WIQ components
Pain –0.63* – – – –
Walking distance –0.59* – – – –
Walking speed –0.53* – – – –
Stair climbing –0.71* – – – –
EuroQol 0.57* 0.44* 0.34* 0.47* 0.55*
SF-36
Physical functioning –0.68* 0.41* 0.51* 0.62* 0.68*
Social functioning –0.59* 0.35* 0.46* 0.37* 0.40*
Role: physical –0.66* 0.46* 0.47* 0.46* 0.53*
Role: emotional –0.51* 0.23* 0.32* 0.28* 0.34*
Pain –0.66* 0.45* 0.34* 0.47* 0.55*
Vitality –0.37* 0.20 0.23* 0.38* 0.28*
Mental health –0.39* 0.18 0.19 0.21* 0.21*
General health perception –0.33* 0.25* 0.24* 0.31* 0.32*
All r values were calculated with Spearman correlation coefficient.
Highest correlation r values are highlighted in bold.
*P  .01.
ICD, Initial claudication distance; ACD, absolute claudication distance.
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with social activities, and problems at work and other
activities as a result of physical health.
Both the ICQ and the WIQ correlated poorly with
resting ABPI measurements. This result suggests that rest-
ing ankle pressures in IC may not accurately reflect the
severity of QOL limitation caused by the condition.
The ICQ is patient friendly and completed in an aver-
age of 3.7 minutes, compared with the CLAU-S question-
naire (18 minutes) and the WIQ (6 minutes). Longer
questionnaires risk poor acceptability and completion rates.
QOL assessment questionnaires can be either self or inter-
viewer completed. Interviewer-completed questionnaires
(eg, the WIQ) have better completion rates but may de-
mand more physician hours to implement and risk a re-
sponse bias because patients may be affected by the pres-
ence of the interviewer who is usually, but not always, their
physician.46,48 The ICQ is designed to be patient com-
pleted. Contrary to the expectation of lower completion
rates, the ICQ fared well (97%). Patient-completed instru-
ments also have the added benefit of follow-up by mail.57
The results of the principal component analysis show
that the items within the ICQ contribute to a single under-
lying health dimension. Other condition-specific instru-
ments intended for claudication (eg, CLAU-S and WIQ)
Table V. Mean changes in instrument scores with self-reported health transition question and SRMs for ICQ,
EuroQol, WIQ, and SF-36 for patients (n  60) undergoing conservative therapy
Instrument
Better (n  16)
About same
(n  34) Worse (n  10) Test for
linearity
F valueMean (SD) SRM Mean (SD) Mean (SD) SRM
ICQ§ –21.02† (15.34) –1.37 –1.42 (9.29) 9.22† (8.74) 1.06 50.63
WIQ
Pain 10.94 (34.12) 0.32 2.21 (20.75) –2.50 (24.86) –0.10 1.90
Walking distance 32.36† (39.23) 0.83 3.90 (18.02) –10.55 (23.11) –0.46 18.80
Walking speed 19.70† (28.39) 0.69 0.45 (13.66) –4.57 (18.13) –0.25 11.69
Stair climbing 9.90 (22.41) 0.44 –6.25† (17.17) 0.42 (13.53) –0.03 3.01
EuroQol 0.14 (0.28) 0.50 0.03 (0.22) –0.07 (0.20) –0.34 5.11
SF-36
Physical functioning 13.44‡ (25.08) 0.54 1.68 (9.90) 13.00 (24.86) 0.52 0.25
Social functioning 4.69 (17.00) 0.28 –6.62 (22.24) 1.25 (10.94) 0.11 0.60
Role: physical 8.85 (19.52) 0.45 –1.35 (19.78) 8.13 (20.21) 0.40 0.18
Role: emotional –6.77 (26.21) –0.26 –10.05‡ (27.81) 2.92 (28.47) 0.10 0.47
Pain 10.94 (26.17) 0.42 –6.25 (22.94) –5.00 (16.87) –0.30 4.20
Vitality 4.82 (13.21) 0.37 –2.82 (16.51) –1.25 (16.61) –0.08 1.37
Mental health 6.09 (18.79) 0.32 –3.68 (13.46) 1.88 (16.68) 0.11 1.03
General health perception 5.61‡ (9.84) 0.57 –6.96‡ (13.55) –11.83 (18.44) –0.64 11.68
*Change scores were calculated with subtracting baseline scores from follow-up scores.
†P  0.01, compared with baseline.
‡P  0.05, compared with baseline.
§ICQ is scored 0 to 100, where 0 is best possible and 100 worst possible health state. WIQ is scored 0 to 100, where 0 is worst possible and 100 best possible
health state. EuroQol is scored 0.59 to 1, where 0.59 is worst possible and 1.0 best possible health state. SF-36 is scored 0 to 100, where 0 is worst
possible and 100 best possible health state.
SD, Standard deviation.
Table VI. ICQ scores with self-reported health transition question for patients undergoing angioplasty and conservative
treatment
No.
Baseline
mean (SD)
Follow-up
mean (SD)
Mean change
(SD) SRM
Angioplasty
Total 40 55.58 (16.83) 33.05 (21.88) 22.53 (18.81)* –1.20
Improvement 31 55.38 (18.60) 29.10 (20.65) 26.28 (17.50)* –1.50
Same or worse 9 56.25 (9.08) 46.63 (21.59) 9.62 (18.29) –0.53
Conservative
Total 60 42.55 (19.54) 37.91 (22.69) 4.64 (15.17) –0.31
Improvement 16 42.42 (19.54) 21.41 (18.41) 21.02 (15.34)* –1.37
Same 34 39.22 (18.55) 37.80 (18.97) 1.41 (9.29) –0.15
Worse 10 55.28 (20.02) 64.50 (16.62) 9.22 (8.74)* 1.06
Change scores were calculated with subtracting baseline scores from follow-up scores.
*P  .01, compared with baseline.
SD, Standard deviation.
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consist of several dimensions, and therefore, users have a
number of scores to contend with, complicating their use as
primary outcome measures.58
The ICQ was the most responsive instrument, showing
the largest SRM for assessing symptomatic change in pa-
tients with claudication, exceeding those for the WIQ, the
EuroQol, and the SF-36. It was the only instrument that
produced a statistically significant change for the group of
patients that reported worse symptoms at 3 months fol-
low-up (Table V). Furthermore, the highly significant lin-
ear relationship between changes in ICQ scores and patient
self-perceived changes in claudication symptoms was fur-
ther evidence of the ICQ as a measure of health outcome
specific to claudication.
A health transition question was used as a criterion for
assessing the responsiveness of the ICQ. Such measures
have been shown to be valid measures of changes in health
and have been used to assess the responsiveness of instru-
ments designed to measure outcome.56,59 However, com-
pared with the ICQ, which attempts to measure all aspects
of QOL that are of importance to patients with claudica-
tion, such health transition questions can only be regarded
as proxy measures of changes in QOL. The development of
the ICQ has shown that patients have numerous concerns
that are much broader than symptoms. The ICQ is capable
of detecting subtle but important QOL changes in patients
with claudication as patients reporting a “same” or “worse”
response in the responsiveness testing stage after angio-
plasty showed better postprocedural ICQ scores (mean
change, 9.62) and patients reporting a “same” response
after conservative therapy showed a smaller ICQ score
improvement (mean change, 1.41). This quality enables
the accurate comparison of treatment options in IC with
regards to health-related QOL changes.
It must be noted that patients in the angioplasty and
conservative treatment groups in the part of this study for
ICQ responsiveness were nonrandomized. The groups also
were not comparable because the angioplasty group had a
higher mean ICQ score (worse symptoms) at baseline
compared with the conservatively treated group (Table VI).
Therefore, the study does not show which treatment
method gives better results but rather allows the assessment
of instrument responsiveness. According to the mean ICQ
scores, at baseline, patients in the conservative treatment
group reported better QOL than those in the angioplasty
group. At 3 months follow-up, patients whose symptoms
improved with angioplasty had the best QOL and patients
whose conditions deteriorated with conservative therapy
appeared to have the worst QOL. Angioplasty appears to
produce better results (78%) for symptomatic improvement
compared with conservative therapy (27%) at 3 months
follow-up, although our data do not allow us to comment
on the long-term durability of this benefit.
The potential drawbacks of instruments like the ICQ
are that such instruments will not be able to entirely com-
pensate for the fact that patients may be biased in their
responses. In the design of such instruments, the known
effects of social desirability (faking good) and deviation
(faking bad) are acknowledged and care is usually taken to
reduce these biases.
The ideal instrument for measuring health-related QOL
outcome in IC should be self administered, easily comprehen-
sible with a brief completion and scoring time, reliable (able to
measure the impact of IC on QOL in a reproducible manner),
valid (measures the effect of IC on QOL), and responsive
(able to detect small but important changes in health from IC
over time or treatment). The ICQ is the only condition-
specific instrument with all these properties that assesses the
effect of IC on QOL from a patient’s perspective. It satisfies
the requirements of a condition-specific endpoint focused
on QOL required in IC as stated by the TASC document.
We recommend its use as an outcome measure in future
trials to evaluate treatment strategy for patients with IC, in
conjunction with a generic instrument.
We thank Mr L. Fligelstone, Ms A. Williams, and Ms S.
Chandler for their help in the assessment for content valid-
ity of the ICQ, Ms M. Ellis and the Department of Vascular
Technology at Charing Cross Hospital for the noninvasive
assessments in clinic, and Mr A. Porter and the Department
of Cardiac Technology at Charing Cross Hospital for the
use of their exercise treadmill.
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